GSK invests $100m to boost vaccine manufacturing at US facility

GSK invests $100m to boost vaccine manufacturing at US facility

Submitted by admin on April 25, 2019 - 11:58am
Source: 
Pharmaceutical Business Review
News Tags: 
GSK
drug manufacturing
vaccines
Montana
Shingrix
Headline: 
GSK invests $100m to boost vaccine manufacturing at US facility
snippet: 

British drugmaker GlaxoSmithKline (GSK) is set to invest $100m to expand long-term vaccine manufacturing capabilities at its Hamilton facility in Montana, US.

Do Not Allow Advertisers to Use My Personal information